Skip to main content
. 2008 Mar 26;105(14):5507–5512. doi: 10.1073/pnas.0800587105

Fig. 4.

Fig. 4.

Distribution of Bcr-Abl kinase domain mutations in subclones resistant to SGX393. ENU-treated Ba/F3 cells expressing native Bcr-Abl were cultured with graded concentrations of SGX393. Each bar represents the relative percentage of the indicated mutant among recovered subclones. Because the percentage of surviving resistant subclones and the concentration of SGX393 are inversely related, a different number of sequenced subclones is represented in the graph for each concentration of SGX393 (SI Table 2). The greatest number of resistant subclones was analyzed at 240 nM SGX393 [resolution of detection: one occurrence per 204 kinase domain-mutant-positive wells (0.5%)]. The detection limits for the remaining SGX393 concentrations are: 120 nM (2.1%; 48 subclones sequenced), 480 nM (1.1%; 90 subclones sequenced), 960 nM (1.8%; 56 subclones sequenced), and 1,920 nM (3.8%; 26 subclones sequenced). In addition, the following mutations accounted for 2.8% of recovered subclones at 240 nM SGX393 only: N322K, E355G, Y417S (1 of 243, 0.4% each), and E258K (4 of 243, 1.6%).